Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 10 studies | 24% ± 8% | |
endothelial cell of lymphatic vessel | 9 studies | 22% ± 8% | |
fibroblast | 8 studies | 23% ± 8% | |
endothelial cell of vascular tree | 7 studies | 21% ± 6% | |
basal cell | 6 studies | 29% ± 8% | |
respiratory goblet cell | 6 studies | 30% ± 10% | |
epithelial cell | 5 studies | 29% ± 10% | |
club cell | 4 studies | 25% ± 9% | |
secretory cell | 4 studies | 34% ± 11% | |
squamous epithelial cell | 3 studies | 37% ± 25% | |
vein endothelial cell | 3 studies | 21% ± 2% | |
endothelial cell of artery | 3 studies | 18% ± 2% | |
smooth muscle cell | 3 studies | 17% ± 2% |
Insufficient scRNA-seq data for expression of A4GALT at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
prostate | 100% | 3501.98 | 245 / 245 | 98% | 26.62 | 490 / 502 |
kidney | 100% | 4321.31 | 89 / 89 | 95% | 60.94 | 859 / 901 |
uterus | 100% | 2985.81 | 170 / 170 | 94% | 53.65 | 432 / 459 |
lung | 99% | 2466.87 | 574 / 578 | 83% | 41.84 | 963 / 1155 |
thymus | 100% | 2607.00 | 651 / 653 | 82% | 18.15 | 496 / 605 |
bladder | 100% | 3652.00 | 21 / 21 | 78% | 32.38 | 391 / 504 |
esophagus | 100% | 3727.98 | 1444 / 1445 | 77% | 33.15 | 140 / 183 |
breast | 100% | 3077.12 | 458 / 459 | 77% | 18.54 | 856 / 1118 |
stomach | 100% | 2066.15 | 359 / 359 | 53% | 11.12 | 151 / 286 |
intestine | 96% | 2267.48 | 932 / 966 | 49% | 9.21 | 260 / 527 |
adrenal gland | 95% | 1267.12 | 245 / 258 | 44% | 10.11 | 102 / 230 |
skin | 98% | 1886.26 | 1770 / 1809 | 27% | 4.91 | 127 / 472 |
ovary | 49% | 589.33 | 88 / 180 | 66% | 14.54 | 283 / 430 |
pancreas | 17% | 135.18 | 57 / 328 | 89% | 31.79 | 158 / 178 |
adipose | 100% | 3556.19 | 1204 / 1204 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 23.89 | 1 / 1 |
heart | 100% | 4377.53 | 860 / 861 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3626.47 | 1333 / 1335 | 0% | 0 | 0 / 0 |
spleen | 99% | 1550.04 | 239 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 64.58 | 43 / 45 |
muscle | 86% | 1032.62 | 693 / 803 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 72% | 25.45 | 21 / 29 |
liver | 11% | 108.56 | 25 / 226 | 24% | 4.79 | 98 / 406 |
brain | 13% | 103.38 | 353 / 2642 | 18% | 2.49 | 127 / 705 |
peripheral blood | 17% | 291.20 | 157 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0001576 | Biological process | globoside biosynthetic process |
GO_0006688 | Biological process | glycosphingolipid biosynthetic process |
GO_0006493 | Biological process | protein O-linked glycosylation |
GO_0007009 | Biological process | plasma membrane organization |
GO_0000139 | Cellular component | Golgi membrane |
GO_0016020 | Cellular component | membrane |
GO_0008375 | Molecular function | acetylglucosaminyltransferase activity |
GO_0050512 | Molecular function | lactosylceramide 4-alpha-galactosyltransferase activity |
GO_0015643 | Molecular function | toxic substance binding |
GO_0008378 | Molecular function | galactosyltransferase activity |
Gene name | A4GALT |
Protein name | Mutant alpha-1,4 galactosyltransferase Mutant alpha 1,4-galactosyltransferase Alpha 14-galactosyltransferase isoform 2 Truncated alpha 1,4-galactosyltransferase Truncated alpha1,4-galactosyltransferase Alpha-1,4-galactosyltransferase Putative alpha 1,4-galactosyltransferase transcript variant IV Lactosylceramide 4-alpha-galactosyltransferase (EC 2.4.1.228) (Alpha-1,4-N-acetylglucosaminyltransferase) (Alpha-1,4-galactosyltransferase) (Alpha4Gal-T1) (CD77 synthase) (Globotriaosylceramide synthase) (Gb3 synthase) (P1/Pk synthase) (UDP-galactose:beta-D-galactosyl-beta1-R 4-alpha-D-galactosyltransferase) Lactosylceramide 4-alpha-galactosyltransferase (EC 2.4.1.228) (Alpha-1,4-N-acetylglucosaminyltransferase) (Alpha-1,4-galactosyltransferase) (Globotriaosylceramide synthase) (UDP-galactose:beta-D-galactosyl-beta1-R 4-alpha-D-galactosyltransferase) |
Synonyms | A4GALT1 A14GALT |
Description | FUNCTION: Catalyzes the transfer of galactose from UDP-alpha-D-galactose to lactosylceramide/beta-D-galactosyl-(1->4)-beta-D-glucosyl-(1<->1)-ceramide(d18:1(4E)) to produce globotriaosylceramide/globoside Gb3Cer (d18:1(4E)) . Also able to transfer galactose to galactosylceramide/beta-D-Gal-(1<->1')-Cer . Globoside Gb3Cer is a glycosphingolipid of the globo serie, one of the major types of neutral root structures of glycosphingolipids, that constitute a significant portion of mammalian cell membranes (Probable). Globotriaosylceramide/globoside Gb3Cer in blood and tissue cell membranes is the antigen Pk of blood histogroup P . .; FUNCTION: (Microbial infection) Globotriaosylceramide is one of the cellular ligands for bacterial verotoxins. . |
Accessions | A0A192ZI69 Q7Z7C5 S6CRD2 Q7Z7C2 ENST00000642412.2 Q6RJV8 Q6RJW0 Q6RJV6 ENST00000249005.3 S6CQT5 ENST00000381278.4 Q7Z7C4 S6CPX2 A0A0S2Z5J1 B0L3P6 Q9NPC4 Q7Z7C3 Q540I6 M1KVK7 ENST00000401850.5 F2VPV5 R4X5Z8 A0A0S2Z671 Q540I5 B0L3P7 Q6RJV9 Q6RJV7 F2VPV4 Q7Z2I1 Q5D079 Q6RJW1 S6CQ09 Q7Z7C6 |